Form 4: CEL-SCI Corp: Senior Vice President Patricia Prichep Reports Stock Option Grant

Patricia Prichep, Senior Vice President of CEL-SCI Corp, reports the acquisition of 167,000 stock options.

Summary

• On April 19, 2024, Patricia Prichep, Senior Vice President of CEL-SCI Corp, reported the acquisition of 167,000 stock options.
• The options have an exercise price of $1.50.
• The stock options vest in three equal annual installments starting one year after the grant date.
• Following the transaction, Ms. Prichep directly owns 1,893,797 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The grant of stock options to a senior executive aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of three equal annual installments is also a common practice.
• Comparing the size of the grant to similar companies would require more data on CEL-SCI's overall compensation strategy and market capitalization.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.

Key Dates